ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,033.27
-1.11%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Noticias

ALNY Alnylam Pharmaceuticals Inc

143.31
-0.40 (-0.28%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Alnylam Pharmaceuticals Inc ALNY NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.40 -0.28% 143.31 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
144.08 143.00 146.065 143.31 143.71
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202407:00BWAlnylam to Webcast Conference Call Discussing First Quarter..
07/4/202407:00BWAlnylam Presents Positive Results from the KARDIA-2 Phase 2..
20/3/202407:00BWAlnylam to Webcast Investor Event to Discuss Results from..
13/3/202406:30BWAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis..
06/3/202405:50BWAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse,..
05/3/202416:39BWAlnylam annonce des résultats positifs de l’étude KARDIA-2..
05/3/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202406:30BWAlnylam Reports Positive KARDIA-2 Topline Study Results..
04/3/202415:33EDGAR2Form 8-K - Current report
29/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:00EDGAR2Form 144 - Report of proposed sale of securities
27/2/202407:30BWAlnylam to Webcast Presentations at Upcoming March Investor..
20/2/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202407:10EDGAR2Form 8-K - Current report
15/2/202407:00BWAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year..
09/2/202417:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202407:00BWAlnylam to Webcast Conference Call Discussing Fourth Quarter..
19/1/202415:31EDGAR2Form 8-K - Current report
09/1/202407:05BWAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year..
08/1/202406:00EDGAR2Form 8-K - Current report
07/1/202417:00BWAlnylam Announces Preliminary* Fourth Quarter and Full Year..
02/1/202406:30BWAlnylam to Webcast Presentation at 42nd Annual J.P. Morgan..
29/12/202315:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202315:03EDGAR2Form 144 - Report of proposed sale of securities
13/12/202306:30BWAlnylam Highlights Significant Progress with Platform..
11/12/202315:07EDGAR2Form 144 - Report of proposed sale of securities
06/12/202307:00BWAlnylam to Webcast Virtual R&D Day
30/11/202307:00BWAlnylam Ranks #1 on Boston Globe’s Top Places to Work List..
12/11/202311:08BWAlnylam présente des résultats positifs de l'étude KARDIA-1..
11/11/202315:00BWAlnylam Presents Positive Results from the KARDIA-1 Phase 2..
07/11/202307:00BWAlnylam to Webcast Presentations at Upcoming November..
02/11/202307:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202307:10EDGAR2Form 8-K - Current report
02/11/202307:00BWAlnylam Pharmaceuticals Reports Third Quarter 2023 Financial..
26/10/202313:00BWAlnylam Recognized by Science Magazine as Top Employer for..
25/10/202316:19BWAlnylam Announces Publication of Results from APOLLO-B Phase..
25/10/202310:05BWAlnylam Reports Additional Positive Interim Phase 1 Results..
19/10/202307:00BWAlnylam to Webcast Conference Call Discussing Third Quarter..
10/10/202306:30EDGAR2Form 8-K - Current report
10/10/202306:02IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations

Su Consulta Reciente

NASDAQ
ALNY
Alnylam Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados